Fischer Medical

Why is Fischer Medical Ventures Ltd falling/rising?

As of 13-Aug, Fischer Medical Ventures Ltd's stock price is rising to Rs 38.63, up 2.33% after two days of decline, with increased investor interest and strong fundamentals. Despite a year-long decline of 59.56%, recent performance improvements may indicate a shift in market perception.

As of 13-Aug, Fischer Medical Ventures Ltd's stock price is rising, currently at Rs 38.63, reflecting an increase of Rs 0.88 or 2.33%. This upward movement follows a trend reversal after two consecutive days of decline. The stock has shown a notable intraday high of Rs 39.19, which is a 3.81% increase from the previous close.<BR><BR>Several factors contribute to this rise. Firstly, the stock has outperformed the benchmark Sensex over the past week, gaining 2.88% while the Sensex fell by 1.11%. Additionally, there has been a significant increase in investor participation, with delivery volume rising by 60.96% compared to the five-day average, indicating growing interest among investors.<BR><BR>Moreover, the company demonstrates strong fundamentals, with a low Debt to EBITDA ratio of 2.49 times, suggesting a solid ability to service its debt. The company has also experienced impressive long-term growth, with net sales increasing at an annual rate of 283.50% and operating profit growing at 388.62%. <BR><BR>However, it is important to note that despite these positive indicators, the stock has underperformed over the past year, with a decline of 59.56%. This long-term underperformance may still weigh on investor sentiment, but the recent uptick in price suggests a potential shift in market perception, possibly driven by the recent positive performance in the chemicals sector, which has gained by 3.22%.

Which are the latest news on Fischer Medical?

Who are in the management team of Fischer Medical?

The management team of Fischer Medical includes Sejal Soni (Non Executive Director), Ashishkumar Dhakan (Independent Non Executive Director), Krishna Kumar Omprakash Dubey (Independent Director), Jeena Dineshchandra Suthar (Independent Women Director), and Dilip Suryakant Jha (Director & CFO).

The management team of Fischer Medical includes the following individuals:<BR><BR>1. Sejal Soni - Non Executive Director<BR>2. Ashishkumar Dhakan - Independent Non Executive Director<BR>3. Krishna Kumar Omprakash Dubey - Independent Director<BR>4. Jeena Dineshchandra Suthar - Independent Women Director<BR>5. Dilip Suryakant Jha - Director & CFO<BR><BR>If you need more information about any specific member or their roles, feel free to ask!

What does Fischer Medical do?

Fischer Medical Ventures Ltd specializes in trading MRI systems within the Commodity Chemicals industry and is classified as a Small Cap company, with recent net sales of 98 Cr and a net loss of 7 Cr as of March 2026. The company has a market cap of INR 2,503 Cr and key financial metrics include a P/E ratio of 82.00 and a debt-equity ratio of 0.21.

Overview:<BR>Fischer Medical Ventures Ltd is emerging as a leading player in the trading of MRI systems within the Commodity Chemicals industry and is categorized as a Small Cap company.<BR><BR>History:<BR>Fischer Medical Ventures Ltd was incorporated in an unspecified year and has established itself in the medical diagnostic and imaging technologies market. The latest quarterly results reported are for March 2026, showing net sales and profit figures.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 98 Cr (Quarterly Results - Mar 2026) <BR>Most recent Net Profit: -7 Cr (Quarterly Results - Mar 2026) <BR>Market-cap value: INR 2,503 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 82.00 <BR>Industry P/E: 44 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.21 <BR>Return on Equity: 8.08% <BR>Price-to-Book: 6.46 <BR><BR>Contact Details:<BR>Address: 104 1st Fl Bhhind Poisar Depot, Raghuleela Mall Kandivali (W) Mumbai Maharashtra : 400067 <BR>Email: fischerchemicltd@gmail.com <BR>Website: http://www.fischerchemic.in

Who are the peers of the Fischer Medical?

Fischer Medical's peers include Gujarat Alkalies, GHCL, Grauer & Weil, Chemplast Sanmar, J.G.Chemicals, Thirumalai Chem., I G Petrochems, Indo Borax & Ch., and Andhra Sugars. In terms of performance, Fischer Medical has a 1-year return of -59.56%, lower than its peers, with varying management risks and growth rates among them.

Peers: The peers of Fischer Medical are Gujarat Alkalies, GHCL, Grauer & Weil, Chemplast Sanmar, J.G.Chemicals, Thirumalai Chem., I G Petrochems, Indo Borax & Ch., and Andhra Sugars.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL and Chemplast Sanmar, while Average management risk is found at Gujarat Alkalies, Grauer & Weil, Fischer Medical, J.G.Chemicals, Thirumalai Chem., I G Petrochems, and Indo Borax & Ch., and the rest. Growth is Excellent at Fischer Medical, Good at J.G.Chemicals, and Below Average at Gujarat Alkalies, GHCL, Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., I G Petrochems, Indo Borax & Ch., and Andhra Sugars. Capital Structure is Excellent at Gujarat Alkalies, GHCL, Grauer & Weil, J.G.Chemicals, I G Petrochems, and Indo Borax & Ch., Good at Fischer Medical, and Below Average at Chemplast Sanmar, Thirumalai Chem., and Andhra Sugars.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Indo Borax & Ch. at 67.70%, while the peer with the lowest is Chemplast Sanmar at -56.53%. Fischer Medical's own 1-year return is -59.56%, which is lower than both. Additionally, the six-month return is negative for Fischer Medical, GHCL, Grauer & Weil, Chemplast Sanmar, Thirumalai Chem., and Andhra Sugars.

Are Fischer Medical Ventures Ltd latest results good or bad?

Fischer Medical Ventures Ltd's latest Q4 FY26 results show strong revenue growth of 98.76% to ₹97.73 crores, but the company reported a significant net loss of ₹7.10 crores and a sharp decline in operating margin, indicating serious profitability and operational challenges. Overall, the results suggest more distress than success.

Fischer Medical Ventures Ltd's latest results for Q4 FY26 indicate a challenging situation for the company. While the revenue showed impressive growth of 98.76% year-on-year, reaching ₹97.73 crores, this was overshadowed by a significant net loss of ₹7.10 crores, marking a drastic decline of 136.92% compared to the previous quarter's profit of ₹19.23 crores.<BR><BR>The operating margin fell sharply to just 1.03%, the lowest in seven quarters, down from 21.34% in Q3 FY26. This suggests severe operational challenges, including rising costs or pricing pressures that the company has struggled to manage. Additionally, the return on equity (ROE) is at a low 5.57%, well below industry peers, indicating poor capital efficiency.<BR><BR>Overall, the results reflect a company facing significant profitability issues despite strong revenue growth, raising concerns about its ability to sustain this growth and translate it into consistent profits. The combination of a net loss, collapsing margins, and weak returns on equity suggests that the latest results are more indicative of operational distress than success.

How big is Fischer Medical?

As of 14th August, Fischer Medical Ventures Ltd has a market capitalization of 2,554.27 Cr, classifying it as a Small Cap company, with recent Net Sales of 308.58 Cr and a Net Profit of 31.04 Cr.

As of 14th August, Fischer Medical Ventures Ltd has a market capitalization of 2,554.27 Cr, which classifies it as a Small Cap company.<BR><BR>In the latest four quarters, Fischer Medical reported Net Sales of 308.58 Cr and a Net Profit of 31.04 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 337.52 Cr and Total Assets of 456.98 Cr.

Should I buy, sell or hold Fischer Medical Ventures Ltd?

When is the next results date for Fischer Medical Ventures Ltd?

The next results date for Fischer Medical Ventures Ltd is 29 May 2026.

The next results date for Fischer Medical Ventures Ltd is scheduled for 29 May 2026.

Is Fischer Medical technically bullish or bearish?

As of December 2, 2025, Fischer Medical's technical trend is mildly bearish, supported by bearish MACD and moving averages, mixed RSI signals, and a bearish outlook from Dow Theory.

As of 2 December 2025, the technical trend for Fischer Medical has changed from sideways to mildly bearish. The current technical stance is mildly bearish, driven by several key indicators. The MACD is bearish on the weekly and mildly bearish on the monthly, while the moving averages indicate a bearish trend on the daily. Bollinger Bands and KST also reflect a mildly bearish stance on both the weekly and monthly time frames. Although the RSI shows a bullish signal on the monthly, it has no signal on the weekly, indicating mixed momentum. The Dow Theory suggests a mildly bearish outlook on the weekly, with no trend on the monthly. Overall, the combination of these indicators supports a mildly bearish view.

How has been the historical performance of Fischer Medical?

Fischer Medical experienced significant growth from March 2024 to March 2025, with net sales rising to 110.70 Cr from 20.98 Cr, while total liabilities and assets increased to 456.98 Cr. However, profit after tax decreased slightly to 1.70 Cr, and cash flow from operating activities showed a negative trend.

Answer:<BR>The historical performance of Fischer Medical shows significant growth in various financial metrics from March 2024 to March 2025.<BR><BR>Breakdown:<BR>Fischer Medical's net sales surged to 110.70 Cr in March 2025 from 20.98 Cr in March 2024, indicating a substantial increase in total operating income, which also rose to 110.70 Cr from 20.98 Cr. The company's total expenditure, excluding depreciation, increased to 107.38 Cr from 19.12 Cr, primarily driven by a notable rise in the purchase of finished goods, which jumped to 95.28 Cr from 0.08 Cr. Operating profit (PBDIT) improved to 4.81 Cr from 2.36 Cr, while profit before tax increased to 2.71 Cr from 2.11 Cr. However, profit after tax slightly decreased to 1.70 Cr from 1.84 Cr. The consolidated net profit also fell to 1.47 Cr from 1.84 Cr, reflecting a decline in earnings per share to 0.03 from 0.34. On the balance sheet, total liabilities rose significantly to 456.98 Cr from 86.32 Cr, with total assets also increasing to 456.98 Cr from 86.32 Cr. Cash flow from operating activities showed a negative trend, with a cash outflow of 86.00 Cr in March 2025 compared to 7.00 Cr in March 2024, although cash flow from financing activities improved to 314.00 Cr from 37.00 Cr, resulting in a net cash inflow of 103.00 Cr by the end of March 2025.

Is Fischer Medical overvalued or undervalued?

As of June 1, 2024, Fischer Medical is considered very expensive with a PE ratio of 3780.80 and other high valuation metrics, despite impressive returns of 22.64% YTD and 1231.22% over three years, indicating it is overvalued compared to its peers.

As of 1 June 2024, Fischer Medical's valuation grade has moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company's current valuation suggests it is overvalued, particularly highlighted by its staggering PE ratio of 3780.80, an EV to EBITDA of 1624.03, and a Price to Book Value of 18.09. These ratios are exceptionally high compared to its peers, such as Solar Industries with a PE of 123.77 and Godrej Industries, which is considered attractive with a PE of 46.63.<BR><BR>In comparison to its industry, Fischer Medical stands out as very expensive, with its valuation metrics far exceeding those of its competitors. The company's return performance has been impressive, with a YTD return of 22.64% compared to the Sensex's 5.66%, and a remarkable 3-year return of 1231.22% against 49.24% for the Sensex. However, despite these strong returns, the current valuation metrics indicate that Fischer Medical is overvalued in the market.

Who are the top shareholders of the Fischer Medical?

The top shareholder of Fischer Medical is Time Medical International Ventures Pte, holding 51.16%. Other significant shareholders include four Foreign Institutional Investors with 5.38%, and individual investors with 27.48%, while the highest public shareholder is Roopal Hitesh Kawa at 2.78%.

The top shareholders of Fischer Medical include Time Medical International Ventures Pte, which holds the largest stake at 51.16%. Additionally, there are four Foreign Institutional Investors (FIIs) that collectively own 5.38%. The highest public shareholder is Roopal Hitesh Kawa, with a holding of 2.78%. Individual investors also have a significant presence, holding 27.48% of the shares. Overall, the majority of the company's shares are held by promoters, and there are no pledged promoter holdings.

Has Fischer Medical declared dividend?

No Dividend History Available